Production of elastin-like recombinamer-based nanoparticles for docetaxel encapsulation and use as smart drug-delivery systems using a supercritical anti-solvent process

Vallejo, Reinaldo; González‐Valdivieso, Juan; Santos, Mercedes; Rodríguez‐Rojo, Soraya; Arias, Francisco J.

doi:10.1016/j.jiec.2020.10.013

Cited by 20 publications

(6 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CPP-complexed Dox showed significantly increased cell penetration and cell death, even in doxorubicin-resistant breast cancer cells ( Ryu, Kratz, and Raucher 2021 ). Vallejo R prepared docetaxel (DTX) encapsulated, RGD peptide-decorated ELP nanoparticles, suggesting higher cytotoxicity on breast cancer than endothelial cells ( Vallejo et al, 2021 ). Peddi S fused the FKBP12 receptor with ELPs for selective delivery of Rapamycin (Rapa).…”

Section: Drug-loaded Elps For Cancer Therapymentioning

confidence: 99%

Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment

Jiang

Guan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Drug delivery systems (DDSs) have recently gained widespread attention for improving drug loading and delivery efficiency in treating many cancers. Elastin-like polypeptides (ELPs) are synthetic peptides derived from a precursor of elastin (tropoelastin), reserving similar structural and physicochemical properties. ELPs have gained a variety of applications in tissue engineering and cancer therapy due to their excellent biocompatibility, complete degradability, temperature-responsive property, controllable sequence and length, and precisely tuned structure and function. ELPs-based drug delivery systems can improve the pharmacokinetics and biodistribution of therapeutic reagents, leading to enhanced antitumor efficacy. In this review, we summarize the recent application of ELPs in cancer treatment, focusing on the delivery of functional peptides, therapeutic proteins, small molecule drugs, and photosensitizers.

show abstract

Section: Drug-loaded Elps For Cancer Therapymentioning

confidence: 99%

Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment

Jiang

Guan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…144,150 The transition temperature of ELPs could be tuned to enable the solubility of ELPs at room temperature and form insoluble coacervates under physiologically relevant temperatures. 151,152 Therefore, in most research related to ELPs-based longacting formulations, ELPs were usually fused with target protein or peptide therapeutics via biosynthesis of Escherichia coli with the aid of plasmid vector to construct fusion proteins, which may transform into gel under physiological relevant temperature spontaneously and further control the release of fused proteins/peptides. For instance, in the work of Chilkoti et al, glucagon-like peptide 1 (GLP-1) was fused with ELPs and demonstrated stable hypoglycemic efficacy on three diabetic murine models for 10 days and monkey models for 17 days after single subcutaneous (s.c.) injection.…”

Section: Protein-based Systemsmentioning

confidence: 99%

“…ELPs are thermosensitive proteins derived from a human extracellular matrix with excellent mechanical properties and are widely applied in drug delivery and tissue engineering. The most investigated motif of ELPs is the replicates of the VPGXG sequence, in which “X” represents any amino acid except proline. , The transition temperature of ELPs could be tuned to enable the solubility of ELPs at room temperature and form insoluble coacervates under physiologically relevant temperatures. , …”

Section: Protein-based Systemsmentioning

confidence: 99%

Sustained Release Systems for Delivery of Therapeutic Peptide/Protein

et al. 2021

View full text Add to dashboard Cite

Peptide/protein therapeutics have been significantly applied in the clinical treatment of various diseases such as cancer, diabetes, etc. owing to their high biocompatibility, specificity, and therapeutic efficacy. However, due to their immunogenicity, instability stemming from its complex tertiary and quaternary structure, vulnerability to enzyme degradation, and rapid renal clearance, the clinical application of protein/peptide therapeutics is significantly confined. Though nanotechnology has been demonstrated to prevent enzyme degradation of the protein therapeutics and thus enhance the half-life, issues such as initial burst release and uncontrollable release kinetics are still unsolved. Moreover, the traditional administration method results in poor patient compliance, limiting the clinical application of protein/peptide therapeutics. Exploiting the sustained-release formulations for more controllable delivery of protein/peptide therapeutics to decrease the frequency of injection and enhance patient compliance is thus greatly meaningful. In this review, we comprehensively summarize the substantial advancements of protein/peptide sustainedrelease systems in the past decades. In addition, the advantages and disadvantages of all these sustained-release systems in clinical application together with their future challenges are also discussed in this review.

show abstract

“…Since the discovery of the supercritical state in the 19th century, various studies have been carried out, and it has been applied and popularized in petrochemical and environmental protection [ 1 ], thermal power generation [ 2 ], food and drug industries [ 3 , 4 ], biomedical applications [ 5 , 6 , 7 ], material preparation [ 8 , 9 ], etc. This has gradually led to the formation of supercritical fluid extraction technology, supercritical fluid chromatography technology, supercritical dyeing technology, and supercritical drying technology, etc.…”

Section: Introductionmentioning

confidence: 99%

A Bibliometric Analysis and Review of Supercritical Fluids for the Synthesis of Nanomaterials

Zhang

Xing

et al. 2021

Nanomaterials

View full text Add to dashboard Cite

Since the 1990s, supercritical fluids for the synthesis of nanomaterials have been paid more and more attention by researchers and have gradually become one of the most important ways to prepare nanomaterials. In this study, literature data on “supercritical fluids for the synthesis of nanomaterials” from 1998 to 2020 were obtained from the Web of Science database, and the data were processed and analyzed by the bibliometric method combined with Microsoft office 2019, Origin 2018, VOSviewer, and other software, so as to obtain the research status and development trend of “supercritical fluids for the synthesis of nanomaterials”. The results show that since literature on “supercritical fluids for the synthesis of nanomaterials” appeared for the first time in 1998, the number of articles published every year has risen. In terms of this field, China has become the second-largest publishing country after the United States, and China and the United States display a lot of cooperation and exchanges in this field. “Supercritical CO2”, “supercritical water”, “supercritical antisolvent”, “surface modification”, and so on have become the research hotspots of “supercritical fluids for the synthesis of nanomaterials”.

show abstract

Production of elastin-like recombinamer-based nanoparticles for docetaxel encapsulation and use as smart drug-delivery systems using a supercritical anti-solvent process

Cited by 20 publications

References 57 publications

Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment

Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment

Sustained Release Systems for Delivery of Therapeutic Peptide/Protein

A Bibliometric Analysis and Review of Supercritical Fluids for the Synthesis of Nanomaterials

Contact Info

Product

Resources

About